| Market Cap | 473.03K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.04M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -91.00% |
| Sales | 356.88k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -96.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.53 | Shares Outstanding | 477.80M | 52W Low Chg | - |
| Insider Own | - | ROA | -15.94% | Shares Float | 475.90M | Beta | -61.09 |
| Inst Own | 0.02% | ROE | -28.13% | Shares Shorted/Prior | -/- | Price | 0.00000 |
| Gross Margin | 67.63% | Profit Margin | - | Avg. Volume | 3,661 | Target Price | - |
| Oper. Margin | -1,095.65% | Earnings Date | - | Volume | 5,334 | Change | 0.00% |
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
